ProtheraEGFR – AI designed miniproteins against cancer resistance

The ProtheraEGFR consortium will employ the latest developments in generative artificial intelligence (AI) to design novel proteins which interfere with cancer resistance. The consortium comprises structural biologists from the Max-Delbrück-Center for Molecular Medicine, AI specialists from the Helmholtz Centers Jülich and Dresden-Rossendorf and clinical researchers from the Medical Center University of Freiburg. A spin-off for commercializing the obtained therapeutics is envisaged.